Search details
1.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34216247
2.
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Blood
; 120(3): 552-9, 2012 Jul 19.
Article
in English
| MEDLINE | ID: mdl-22184404
3.
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Blood
; 113(18): 4309-18, 2009 Apr 30.
Article
in English
| MEDLINE | ID: mdl-19196658
4.
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Cancer Treat Res Commun
; 28: 100405, 2021.
Article
in English
| MEDLINE | ID: mdl-34329846
5.
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Clin Transl Sci
; 14(1): 277-287, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32770720
6.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood
; 112(4): 1329-37, 2008 Aug 15.
Article
in English
| MEDLINE | ID: mdl-17906076
7.
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
Clin Cancer Res
; 26(10): 2308-2317, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-31969330
8.
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clin Cancer Res
; 14(9): 2775-84, 2008 May 01.
Article
in English
| MEDLINE | ID: mdl-18451245
9.
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.
Cancer Res
; 63(14): 4196-203, 2003 Jul 15.
Article
in English
| MEDLINE | ID: mdl-12874026
10.
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Cancer Res
; 63(19): 6387-94, 2003 Oct 01.
Article
in English
| MEDLINE | ID: mdl-14559828
11.
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.
Oncogene
; 22(38): 6005-12, 2003 Sep 04.
Article
in English
| MEDLINE | ID: mdl-12955079
12.
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.
Mol Cancer Ther
; 3(8): 921-32, 2004 Aug.
Article
in English
| MEDLINE | ID: mdl-15299075
13.
Recognition of multiple substrate motifs by the c-ABL protein tyrosine kinase.
Comb Chem High Throughput Screen
; 5(1): 83-91, 2002 Feb.
Article
in English
| MEDLINE | ID: mdl-11860343
14.
Use of a SCID mouse model to select for a more aggressive strain of prostate cancer.
Anticancer Res
; 23(3B): 2245-52, 2003.
Article
in English
| MEDLINE | ID: mdl-12894499
15.
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
J Clin Oncol
; 30(16): 1960-5, 2012 Jun 01.
Article
in English
| MEDLINE | ID: mdl-22291084
16.
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Mol Cancer Ther
; 8(9): 2616-24, 2009 Sep.
Article
in English
| MEDLINE | ID: mdl-19723891
17.
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Proc Natl Acad Sci U S A
; 102(33): 11858-63, 2005 Aug 16.
Article
in English
| MEDLINE | ID: mdl-16087880
Results
1 -
17
de 17
1
Next >
>>